Literature DB >> 2045828

A review of current drugs for migraine.

J Olesen1.   

Abstract

The current treatments available for migraine are reviewed and may be classified into four basic types. (a) Identification and elimination of migraine trigger factors, which include stress, emotions, fatigue, certain foods and beverages, and certain medications such as oestrogen therapy. (b) Symptomatic treatment of individual attacks. This includes various non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and paracetamol, and ergotamine, dihydroergotamine and phenothiazines. Morphinomimetics, which are often given for migraine, should really be avoided. (c) Prophylactic treatment which is particularly recommended for patients averaging two or more severe migraine attacks per month. Useful drugs include: beta-adrenergic receptor blockers as first choice, e.g. propranolol, timolol, nadolol and metoprolol; 5-hydroxytryptamine blockers, e.g. pizotifen and methysergide; calcium channel blockers; dihydroergotamine; and NSAIDs. (d) Non-drug treatment which is best combined with identification and elimination of trigger factors, and the use of various relaxation techniques. These four treatment types are covered in some detail, however it is clear that none of them is ideal and side-effects present a problem. Clearly, the continued research and development of novel and specific drugs for migraine is vital.

Entities:  

Mesh:

Year:  1991        PMID: 2045828     DOI: 10.1007/bf01642902

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  11 in total

1.  Abuse of prescription drugs.

Authors:  D W Swanson; R L Weddige; R M Morse
Journal:  Mayo Clin Proc       Date:  1973-05       Impact factor: 7.616

Review 2.  Role of calcium entry blockers in the prophylaxis of migraine.

Authors:  J Olesen
Journal:  Eur Neurol       Date:  1986       Impact factor: 1.710

3.  Headache.

Authors:  N H Raskin; O Appenzeller
Journal:  Major Probl Intern Med       Date:  1980

4.  Dose-response curve for the ergotamine-induced decrease of peripheral systolic blood pressure in man.

Authors:  P Tfelt-Hansen; P M Manniche
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1984-09

5.  Migraine is a food-allergic disease.

Authors:  J Monro; C Carini; J Brostoff
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

6.  Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment.

Authors:  J Egger; C M Carter; J Wilson; M W Turner; J F Soothill
Journal:  Lancet       Date:  1983-10-15       Impact factor: 79.321

7.  European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Migraine-Nimodipine European Study Group (MINES).

Authors: 
Journal:  Headache       Date:  1989-11       Impact factor: 5.887

8.  European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Migraine-Nimodipine European Study Group (MINES).

Authors: 
Journal:  Headache       Date:  1989-11       Impact factor: 5.887

9.  Efficacy of beta-blockers in migraine. A critical review.

Authors:  P Tfelt-Hansen
Journal:  Cephalalgia       Date:  1986       Impact factor: 6.292

10.  Intramuscular ergotamine: plasma levels and dynamic activity.

Authors:  P Tfelt-Hansen; L Paalzow
Journal:  Clin Pharmacol Ther       Date:  1985-01       Impact factor: 6.875

View more
  3 in total

Review 1.  A practical guide to the management and prevention of migraine.

Authors:  H C Diener; H Kaube; V Limmroth
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

Review 2.  Orofacial neuralgia. Diagnosis and treatment guidelines.

Authors:  C Feinmann; R Peatfield
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

3.  Palladium-Catalyzed C-H Arylation of α,β-Unsaturated Imines: Catalyst-Controlled Synthesis of Enamine and Allylic Amine Derivatives.

Authors:  Minyan Li; María González-Esguevillas; Simon Berritt; Xiaodong Yang; Ana Bellomo; Patrick J Walsh
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-05       Impact factor: 15.336

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.